688302 海创药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-5.429-12.169-15.590-19.926-25.400
总资产报酬率 ROA (%)-4.353-10.276-13.984-18.233-22.191
投入资产回报率 ROIC (%)-4.916-11.393-15.252-19.603-24.075

边际利润分析
销售毛利率 (%)97.33698.6188.428--53.571
营业利润率 (%)-99.594-666.148-54,378.903---18,261.390
息税前利润/营业总收入 (%)-99.483-701.511-57,305.242---18,717.369
净利润/营业总收入 (%)-102.270-670.510-54,382.772---18,264.523

收益指标分析
经营活动净收益/利润总额(%)119.670121.841108.868110.388112.894
价值变动净收益/利润总额(%)-13.377-11.185-6.571-8.443-9.582
营业外收支净额/利润总额(%)2.6110.6480.0010.0020.017

偿债能力分析
流动比率 (X)6.1737.1996.02610.73711.653
速动比率 (X)6.0627.1766.02610.73711.653
资产负债率 (%)20.86318.79712.4378.3458.627
带息债务/全部投入资本 (%)7.1277.6361.734-0.3471.502
股东权益/带息债务 (%)1,269.2911,186.9275,561.381-28,589.6436,511.928
股东权益/负债合计 (%)379.328432.012704.0761,098.2881,059.170
利息保障倍数 (X)-35.77722.61819.58625.53041.333

营运能力分析
应收账款周转天数 (天)19.1970.0470.000--0.000
存货周转天数 (天)1,115.0701,813.9155.430--2.676